Medication info
Nelson Pregabalin Capsule 150 mg (Pregabalin)

Nelson Pregabalin Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Korea Nelson Pharmaceutical Co., Ltd.
Appearance
A firm capsule with a white powder that is white or light yellow in color.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201603533 · Approved 2016.06.16 · Insurance code 665506870

Summary

Main use
Treatment of neuropathic pain and partial seizures; treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be started at 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be started at 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The starting dose is 75 mg twice daily (150 mg daily); based on efficacy and tolerability, this may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Creatinine clearance ≥60: starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance ≥30 -<60: starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance ≥15 -<30: starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance <15: starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Korea Nelson Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and partial seizures; treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia
View approved original text

This medication is effective in treating peripheral and central neuropathic pain in adults, assisting in the management of partial seizures in epilepsy patients, and helps in the treatment of fibromyalgia. It is effective in improving symptoms related to various neurological disorders and pain.

How to take

Adult dose

This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be started at 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be started at 150 mg daily. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may then be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg daily. The starting dose is 75 mg twice daily (150 mg daily); based on efficacy and tolerability, this may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies have also been conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Creatinine clearance ≥60: starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance ≥30 -<60: starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance ≥15 -<30: starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance <15: starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, 100 mg, single dose TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: Supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication is an anticonvulsant, and there is an increased risk of thoughts or actions of suicide during treatment, so immediate consultation with a healthcare provider is necessary if symptoms of depression or mood changes occur. Patients with hypersensitivity to this medication or those with genetic lactose metabolism disorders should not take it. Diabetic patients may need dose adjustments of blood sugar control medications due to weight gain while taking this medication. If symptoms of angioedema occur, the medication should be discontinued immediately, and caution is required for the elderly due to the risk of falls from dizziness or drowsiness. Visual disturbances such as blurred vision may occur, so any abnormalities should be reported to a healthcare provider. Discontinuing this medication suddenly may result in withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so it is advisable to taper off the dose gradually. Patients with a history of substance abuse should exercise caution due to the potential for misuse or dependence on this medication. Patients with reduced kidney function require dose adjustments, and those with heart disease should also use this medication cautiously. Combining this medication with opioid analgesics may increase the risk of central nervous system depression, so caution should be exercised. In early pregnancy, there is a risk of fetal malformation, so pregnant women should not take this medication, and women of childbearing potential should use effective birth control while on this medication. Breastfeeding mothers are advised to either stop nursing or discontinue this medication since it can pass into breast milk. Patients should check whether this medication causes dizziness or drowsiness before driving or operating machinery and should avoid dangerous activities if symptoms are present. Severe skin reactions can rarely occur, so if symptoms such as rash or swelling appear, discontinue use immediately and consult a healthcare provider. In case of overdose, symptoms may include drowsiness, confusion, and depression, and treatment such as blood dialysis may be necessary.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
Show 214 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal ideation
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • depression
  • euphoria
  • decreased libido
  • insomnia
  • depersonalization
  • paraphilia
  • restlessness
  • agitation
  • mood swings
  • emotional depression
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination disorder
  • balance disorders
  • memory loss
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory impairment
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • reflex impairment
  • motor abnormalities
  • psychomotor agitation
  • positional dizziness
  • hyperesthesia
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • muscle weakness syndrome
  • olfactory abnormalities
  • loss of taste
  • writing impairment
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • ocular edema
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • ocular irritation
  • mydriasis
  • during vibration
  • depth perception changes
  • strabismus
  • visual clarity
  • vertigo
  • hyperacusis
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tightness
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • swelling
  • gait abnormalities
  • falling
  • feeling drunk
  • sensation abnormalities
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorder
  • drowsiness
  • confusional state
  • depression
  • agitation
  • restlessness
  • worsening of seizures
  • ataxia
  • dysarthria
  • sensory abnormalities
  • memory impairment
  • attention deficit
  • constipation
  • gastrointestinal disorders
  • bloody stools
  • increased BUN
  • difficulty urinating
  • tinnitus
  • skin diseases

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture, at room temperature between 15 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness for a longer period.

Appearance and packaging

Appearance

A firm capsule with a white powder that is white or light yellow in color.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.